Evidence map›Paper›PMID 34121205›Full record

ArticleTransfusion2021

SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance.

Clara Di Germanio, Graham Simmons, Kathleen Kelly, Rachel Martinelli, Orsolya Darst, Mahzad Azimpouran, Mars Stone, Kelsey Hazegh, Eduard Grebe, Shuting Zhang and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Clara Di GermanioVitalant Research Institute, San Francisco, California, USA.
Graham SimmonsVitalant Research Institute, San Francisco, California, USA.
Kathleen KellyVitalant Research Institute, Denver, Colorado, USA.
Rachel MartinelliVitalant Research Institute, San Francisco, California, USA.
Orsolya DarstVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0003-3682-4338
Mahzad AzimpouranVitalant Research Institute, San Francisco, California, USA.
Mars StoneVitalant Research Institute, San Francisco, California, USA.
Kelsey HazeghVitalant Research Institute, Denver, Colorado, USA.
Eduard GrebeVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-7046-7245
Shuting ZhangInfectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA.
Peijun MaInfectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA.
Marek OrzechowskiInfectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA.
James E GomezInfectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA.
Jonathan LivnyInfectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA.
Deborah T HungInfectious Disease and Microbiome Program, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA.
Ralph VassalloVitalant, Scottsdale, Arizona, USA.ORCID 0000-0001-8754-047X
Michael P BuschVitalant Research Institute, San Francisco, California, USA.
Larry J DumontVitalant Research Institute, Denver, Colorado, USA.ORCID 0000-0002-1715-0748
Broad Institute · USPacific Research Institute · USUniversity of California, San Francisco · USVitalant · USVitalant · US

Funding

Abbott DiagnosticsBroad InstituteU.S. Biomedical Advanced Research and Development Authority variousVitalant internal funding
6 · The paper itself

Abstract

backgroundAntibody response duration following severe acute respiratory syndrome coronavirus 2 infection tends to be variable and depends on severity of disease and method of detection. STUDY DESIGN AND

methodsCOVID-19 convalescent plasma from 18 donors was collected longitudinally for a maximum of 63-129 days following resolution of symptoms. All the samples were initially screened by the Ortho total Ig test to confirm positivity and subsequently tested with seven additional direct sandwich or indirect binding assays (Ortho, Roche, Abbott, Broad Institute) directed against a variety of antigen targets (S1, receptor binding domain, and nucleocapsid [NC]), along with two neutralization assays (Broad Institute live virus PRNT and Vitalant Research Institute [VRI] Pseudovirus reporter viral particle neutralization [RVPN]).

resultsThe direct detection assays (Ortho total Ig total and Roche total Ig) showed increasing levels of antibodies over the time period, in contrast to the indirect IgG assays that showed a decline. Neutralization assays also demonstrated declining responses; the VRI RVPN pseudovirus had a greater rate of decline than the Broad PRNT live virus assay. DISCUSSION: These data show that in addition to variable individual responses and associations with disease severity, the detection assay chosen contributes to the heterogeneous results in antibody stability over time. Depending on the scope of the research, one assay may be preferable over another. For serosurveillance studies, direct, double Ag-sandwich assays appear to be the best choice due to their stability; in particular, algorithms that include both S1- and NC-based assays can help reduce the rate of false-positivity and discriminate between natural infection and vaccine-derived seroreactivity.

Indexed as

Blood DonorsAntibodies, NeutralizingAntibodies, ViralCOVID-19Host-Pathogen InteractionsHumansImmunoglobulin GSARS-CoV-2Seroepidemiologic StudiesSerologic TestsSeverity of Illness IndexAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Gantibody waningconvalescent plasmaSARS-CoV-2 antibody

Identifiers

PMID34121205
PMCPMC8447038
OpenAlexW3168438559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.